Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Procaps Group S.A. (PROCF)
Luxembourg City, LU
Procaps Group S.A. is a global pharmaceutical company engaged in the development, manufacturing, and commercialization of a diverse range of medical solutions. The company's portfolio encompasses branded prescription drugs, addressing numerous therapeutic areas such as women's health, pain relief, dermatological conditions, digestive health, growth and development, cardiovascular issues, vision care, central nervous system disorders, and respiratory ailments. Additionally, it supplies pharmaceutical products for hospital use, including antibiotics, anticoagulants, personal protective equipment, immunosuppressants, oncology treatments, and analgesics. Its consumer healthcare segment features a wide array of over-the-counter (OTC) products across approximately eight therapeutic categories, including gastrointestinal, skincare, cough and cold remedies, pain management, urology, and various vitamins, minerals, and dietary supplements. This expansive offering covers numerous categories like anti-infectives, cardiovascular support, hormonal regulators, metabolic aids, and nervous system treatments. Moreover, Procaps provides comprehensive solutions for diabetes management, encompassing blood glucose monitors, telemonitoring devices, oral anti-diabetic medications, cosmeceuticals, and insulin delivery systems. The firm also operates as a contract drug development and manufacturing (CDMO) provider for other pharmaceutical enterprises, with a recognized specialization in soft gelatin capsule technologies. Established in 1977, Procaps Group S.A. is headquartered in Luxembourg.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | -0.40% | +3.31% | -83.33% | -0.40% | -98.28% | -99.45% | -99.74% | -99.74% | -99.74% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+5.1% Q4'23: +9.5% (vs Q4'22)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+11.1% Q4'23: -113.7% (vs Q4'22)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+15.1% ★ Q4'23: +15.8% (vs Q4'22)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+20.5% ★ Q4'23: +0.6% (vs Q4'22)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+27.7% ★ Q4'23: +0.6% (vs Q4'22)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.0% Q4'23: -0.6% (vs Q4'22)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×2.85× Q4'23: 12.82× (vs Q4'22)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2024 actual |
|---|---|
| Revenue |
460.35M
est.
|
| EBITDA |
171.35M
est.
|
| EBIT |
157.30M
est.
|
| Net Income |
27.81M
est.
|
| SGA |
270.82M
est.
|
| EPS |
0.28
est.
|
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR Portfolio Emerging Markets ETF SPEM | 0.00% | — | 0.07% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Alexandre Etienne Weinstein | Executive Chairman | — | male |
| Daniel Bernal | Interim Chief Financial Officer | — | male |
| Luis Alberto Palacios Aragon | Chief Commercial Officer | — | male |
| Melissa Angelini | Interim Chief Executive Officer | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PROCF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
